Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses
Taraban, Vadim Y., Rowley, Tania F., O'Brien, Lyn, Chan, H.T. Claude, Haswell, Linsey E., Green, Michael H.A, Tutt, Alison L., Glennie, Martin J. and Al-Shamkhani, Aymen (2002) Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. European Journal of Immunology, 32, (12), 3617-3627. (doi:10.1002/1521-4141(200212)32:12<3617::AID-IMMU3617>3.0.CO;2-M).
Full text not available from this repository.
his study addresses the relative importance of CD134 (OX40) and CD137 (4-1BB) in the costimulation of CD4+ and CD8+ T cells under comparable conditions of antigenic stimulation. We demonstrate that CD134 is capable of directly costimulating CD8+ T cells. However, costimulation of CD8+ T cells by CD134 is less potent than that triggered by CD137. The higher costimulatory activity of CD137, when compared with CD134, correlates well with its faster expression kinetics and higher levels on CD8+ T cells. Furthermore, induction of CD137 expression on CD8+ T cells is highly sensitive to low levels of TCR stimulation, which is in contrast with CD134. Conversely, CD134 is more effective than CD137 in costimulating CD4+ T cells. This, however, could not be attributed to differential expression. We also demonstrate that the transient nature of CD134 and CD137 expression on activated CD4+ T cells is the resultof proteolytic shedding. Consistent with the greater ability of CD137 to costimulate CD8+ T cells, stimulation of CD137 in vivo is considerably more effective than CD134 in augmenting anti-tumor immune responses. Therefore, agents that stimulate signaling via CD137 are likely to be more useful in clinical conditions where highly effective CD8+ CTL responses are required.
|Keywords:||T cell activation, costimulation, tumor immunity, immunotherapy|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Q Science > QR Microbiology > QR180 Immunology
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Cancer Sciences
|Date Deposited:||21 Apr 2006|
|Last Modified:||01 Jun 2011 02:03|
|Contributors:||Taraban, Vadim Y. (Author)
Rowley, Tania F. (Author)
O'Brien, Lyn (Author)
Chan, H.T. Claude (Author)
Haswell, Linsey E. (Author)
Green, Michael H.A (Author)
Tutt, Alison L. (Author)
Glennie, Martin J. (Author)
Al-Shamkhani, Aymen (Author)
|Contact Email Address:||email@example.com|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)